Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: Correlation with pathological outcome

Sandri, Maria Teresa; Bottari, Fabio; Franchi, D.; Boveri, Sara; Candiani, Massimo; Ronzoni, Stefania; Peiretti, Michele; Radice, Davide; Passerini, Rita; Sideri, Mario

doi:10.1016/j.ygyno.2012.11.026

Cited by 89 publications

(67 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, there are conflicting reports regarding the benefit of HE4 and ROMA, with some studies showing that HE4 and ROMA can better predict the likelihood of malignancy than CA125 [15][16][17], while others show no benefit of HE4 and ROMA [18,19]. In addition, it is important to remember that detection of HE4 has been applied in clinical centers in South China for just one and a half years.…”

Section: Introductionmentioning

confidence: 99%

Modification of cut-off values for HE4, CA125 and the ROMA algorithm for early-stage epithelial ovarian cancer detection: Results from 1021 cases in South China

Zhong

et al. 2016

Clinical Biochemistry

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Modification of cut-off values for HE4, CA125 and the ROMA algorithm for early-stage epithelial ovarian cancer detection: Results from 1021 cases in South China

Zhong

et al. 2016

Clinical Biochemistry

View full text Add to dashboard Cite

“…On the other hand, the manufacturer's manual recommended to evaluate the results of HE4 regardless of the menopausal status [21]. The ROMA results are also known to be significantly different between pre- and postmenopausal women, and the normal cut-off value depends on the menopausal status [15,22]. In our analysis, only the ROMA values were significantly different between pre- and postmenopausal patients with peritoneal dissemination.…”

Section: Discussionmentioning

confidence: 70%

“…This value showed notable diagnostic performance in distinguishing epithelial ovarian carcinoma (EOC) from benign ovarian tumors [13]. Although there is increasing evidence of the ROMA being a valuable marker for the prediction of malignancy, its usefulness as a predictive marker for peritoneal dissemination is limited [14,15]. Therefore, the aim of this study is to determine appropriate ROMA, CA125, and HE4 cut-off values and to evaluate the efficacy of these markers as predictors of peritoneal dissemination.…”

Section: Introductionmentioning

confidence: 99%

The Risk of Ovarian Malignancy Algorithm (ROMA) as a Predictive Marker of Peritoneal Dissemination in Epithelial Ovarian Cancer Patients

Ikeda

Kurosaki²,

Miyara

et al. 2015

Oncol Res Treat

View full text Add to dashboard Cite

Background: This study aimed to determine the efficacy of the risk of ovarian malignancy algorithm (ROMA), calculated using the carbohydrate antigen 125 (CA125) and human epididymis protein 4 (HE4) levels and the menopausal status, as a predictor of peritoneal dissemination in ovarian cancer. Methods: The CA125 and HE4 levels and the ROMA were compared between ovarian cancer patients (n = 122) with or without peritoneal dissemination. The sensitivity, specificity, positive predictive value, and negative predictive value were calculated, and the results were compared with those of computed tomography (CT). Results: The CA125, HE4, and ROMA values differed significantly depending on the presence of peritoneal dissemination (p < 0.0001). The cut-off values were 181 U/ml for CA125, 161 pmol/ml for HE4, 44% for the ROMA (premenopausal), and 86% for the ROMA (postmenopausal). Among these markers, the ROMA (premenopausal) was the strongest predictor of peritoneal dissemination, with a specificity of 85.0% and a positive predictive value of 81.3%. In addition, the detection rates of small disseminations with less than 2 cm in diameter for the ROMA (93%) and HE4 (60%) were superior to that of CT (53%). Conclusions: The ROMA was a significant predictor of peritoneal dissemination and may be superior to CT for the detection of patients with small disseminations.

show abstract

“…Unfortunately, we do not know the value of the HE4 marker at the moment of establishing the ovarian cancer diagnosis in the reported female patient because in the 1990s this marker had not been determined yet. However, it is highly probable that it was increased because HE4 sensitivity in the ovarian cancer diagnostics is higher than 80%, and in combination with CA 125 (ROMA - Risk of Ovarian Malignancy Algorithm) even higher than 90% [16]. …”

Section: Discussionmentioning

confidence: 99%

A Rare Case of Peritoneal Disseminated Angiosarcoma 20 Years after Ovarian Cancer Diagnosis

Chudecka‐Głaz¹,

Menkiszak²,

Kuźniak³

et al. 2013

Gynecol Obstet Invest

View full text Add to dashboard Cite

Angiosarcoma is a rare form of sarcoma which may be either a primary tumor or it may result from previous irradiation because of another tumor. In this paper, we present a case of a female patient diagnosed as having peritoneal disseminated angiosarcoma 20 years after ovarian cancer treatment (surgery, chemotherapy and radiotherapy). The case was very atypical because of an extremely rare peritoneal location and disseminated nature of the changes. Based on the initial histological picture, poorly differentiated cancer metastasis was diagnosed, suggesting a recurrence of the ovarian cancer that had been diagnosed earlier. The time elapsed from the ovarian cancer diagnosis, history of the previous irradiation and concentration of tumor markers were the only additional clinical data provided to the pathologists, which ultimately contributed to a correct diagnosis. The case we present herein shows and emphasizes the importance of proper communication between a clinician and a pathologist, which is a prerequisite for a correct diagnosis and, consequently, for proper treatment of patients. It also confirms the high specificity of the HE4 (human epididymis protein 4) marker in the monitoring of ovarian cancer, which was within normal limits in spite of peritoneal tumor dissemination.

show abstract

Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: Correlation with pathological outcome

Cited by 89 publications

References 42 publications

Modification of cut-off values for HE4, CA125 and the ROMA algorithm for early-stage epithelial ovarian cancer detection: Results from 1021 cases in South China

Modification of cut-off values for HE4, CA125 and the ROMA algorithm for early-stage epithelial ovarian cancer detection: Results from 1021 cases in South China

The Risk of Ovarian Malignancy Algorithm (ROMA) as a Predictive Marker of Peritoneal Dissemination in Epithelial Ovarian Cancer Patients

A Rare Case of Peritoneal Disseminated Angiosarcoma 20 Years after Ovarian Cancer Diagnosis

Contact Info

Product

Resources

About